1. Home
  2. WINA vs REPL Comparison

WINA vs REPL Comparison

Compare WINA & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Winmark Corporation

WINA

Winmark Corporation

N/A

Current Price

$272.30

Market Cap

1.1B

ML Signal

N/A

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

N/A

Current Price

$20.76

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
WINA
REPL
Founded
1988
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.3B
IPO Year
2006
2018

Fundamental Metrics

Financial Performance
Metric
WINA
REPL
Price
$272.30
$20.76
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
★ $23.33
AVG Volume (30 Days)
70.5K
★ 3.2M
Earning Date
10-14-2026
10-28-2026
Dividend Yield
★ 2.94%
N/A
EPS Growth
★ 3.76
N/A
EPS
★ 8.51
N/A
Revenue
★ $86,055,700.00
N/A
Revenue This Year
$12.61
N/A
Revenue Next Year
$44.75
$513.15
P/E Ratio
$32.27
★ N/A
Revenue Growth
★ 5.86
N/A
52 Week Low
$261.71
$1.50
52 Week High
$488.83
$23.64

Technical Indicators

Market Signals
Indicator
WINA
REPL
Relative Strength Index (RSI) 42.06 65.49
Support Level $261.71 $7.11
Resistance Level $293.75 N/A
Average True Range (ATR) 10.08 1.65
MACD 0.02 0.50
Stochastic Oscillator 34.22 75.81

Price Performance

Historical Comparison
WINA
REPL

About WINA Winmark Corporation

Winmark Corp is a franchisor of value-oriented retail store concepts that buy, sell, and trade gently used merchandise. The company has one reportable segment, including Franchising, and one non-reportable segment, Leasing. The franchising segment franchises value-oriented retail stores that buy, sell, trade, and consign merchandise as well as provide strategic consulting services relating to franchising. The leasing segment includes the middle-market equipment leasing business and small-ticket financing business. It generates a majority of its revenue from the Franchising segment.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.

Share on Social Networks: